Evox Therapeutics Analysis
What is Evox Therapeutics?
Proprietary ExoEdit™ gene editing in exosomes for rare neurodegenerative diseases
Location
Oxford, United Kingdom
Employees
11-50
Founded
2016
Product Features & Capabilities
- ExoEdit™ gene editing platform
- Exosome-based CRISPR/Cas delivery
- Targeted delivery to central nervous system
- Therapeutic pipeline for rare neurodegenerative diseases
Use Cases
Deliver CRISPR/Cas gene editing to brain cells in patients with rare neurodegenerative diseases; Target and knock-down disease-causing genes in central nervous system; Develop therapies for conditions like ALS and Parkinson's disease; Advance clinical translation of exosome-based gene therapies; Conduct preclinical studies in animal models of neurodegeneration
Other Considerations
Named in Nature Biomedical Engineering publication; Co-founded by Professor Matthew Wood and Dr. Per Lundin; Backed by Oxford Sciences Innovation; Developed ExoEdit™ technology from Oxford and Karolinska Institutet research; Pipeline includes therapies for ALS and Parkinson's disease
See something that needs updating? Suggest edits to this profile.